Melanoma antigens are biomarkers for ipilimumab response

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F17%3A43912193" target="_blank" >RIV/00216208:11120/17:43912193 - isvavai.cz</a>

Alternative codes found

RIV/00064173:_____/17:N0000062

Result on the web

<a href="http://dx.doi.org/10.1111/jdv.13940" target="_blank" >http://dx.doi.org/10.1111/jdv.13940</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/jdv.13940" target="_blank" >10.1111/jdv.13940</a>

Result language

angličtina

Original language name

Melanoma antigens are biomarkers for ipilimumab response

Original language description

BACKGROUND: Novel immunotherapy modalities significantly improve survival of patients with metastatic melanoma. However, CTLA-4-blocking monoclonal antibody ipilimumab is effective only in a small proportion of patients. Biomarkers for prediction of treatment response are indispensably needed. OBJECTIVE: To determine the utility of multimarker detection of circulating melanoma cells as prognostic and pharmacodynamic biomarker in patients with metastatic melanoma treated with ipilimumab. METHODS: Patients (n=62) with metastatic melanoma in unresectable stage III or metastatic stage IV treated with ipilimumab were recruited prospectively. The values of 4 melanoma markers on circulating cells Melan-A, gp100, MAGE-3 and MIA prior to the treatment and within the therapy were compared to the data collected at baseline - after the melanoma surgery. RESULTS: The immunotherapy pretreatment marker level was found to be prognostic of overall survival, lower levels were linked to longer survival time. Moreover, longitudinal follow-up of melanoma markers in patients treated with ipilimumab correlates with therapy response. A decline of marker levels by &gt; 30% at week 6 (in 83% of the responding subjects) to week 9 (in all responders) of ipilimumab administration was associated with response to therapy. Elevation of the tumor markers during the treatment precedes clinical progression and gives an early warning of treatment failure. CONCLUSION: Melanoma circulating cells hold potential as predictive and pharmacodynamic biomarker of immunotherapy.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30216 - Dermatology and venereal diseases

Project

<a href="/en/project/NT14440" target="_blank" >NT14440: Detection of circulating melanoma cells for evaluation of immunotherapeutic effect</a><br>

Continuities

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of the European Academy of Dermatology and Venereology

ISSN

0926-9959

e-ISSN

—

Volume of the periodical

31

Issue of the periodical within the volume

2

Country of publishing house

GB - UNITED KINGDOM

Number of pages

8

Pages from-to

252-259

UT code for WoS article

000393573600009

EID of the result in the Scopus database

2-s2.0-85010644702